News >

Novel Treatments Expand Second-Line Options in ITP

Jessica Hergert
Published: Friday, May 22, 2020

Ivy P. Altomare, MD, associate professor of medicine, Department of Medicine, Duke University School of Medicine, and medical oncologist, Duke Cancer Network

Ivy P. Altomare, MD

Although steroids remain the standard frontline treatment for patients with immune thrombocytopenia (ITP), the armamentarium in the second-line setting is rapidly expanding, according to Ivy P. Altomare, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication